Artificial intelligence for target prostate biopsy outcomes prediction the potential application of fuzzy logic

Checcucci, Enrico; Rosati, Samanta; Cillis, Sabrina De; Vagni, M.; Giordano, Noemi; Piana, Alberto; Granato, Stefano; Luca, Stefano De; Fiori, Cristian; Balestra, Gabriella; Porpiglia, Francesco

doi:10.1038/s41391-021-00441-1

Cited by 15 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment of PCa is a global health concern ( 68 , 69 ), and the application of AI in PCa will also have an important impact on the diagnosis and treatment of PCa ( 70 ). However, only 82 countries participated in the research of AI in PCa, and more than half of the countries published less than 10 papers.…”

Section: Discussionmentioning

confidence: 99%

The Global Research of Artificial Intelligence on Prostate Cancer: A 22-Year Bibliometric Analysis

Shen

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundWith the rapid development of technology, artificial intelligence (AI) has been widely used in the diagnosis and prognosis prediction of a variety of diseases, including prostate cancer. Facts have proved that AI has broad prospects in the accurate diagnosis and treatment of prostate cancer.ObjectiveThis study mainly summarizes the research on the application of artificial intelligence in the field of prostate cancer through bibliometric analysis and explores possible future research hotspots.MethodsThe articles and reviews regarding application of AI in prostate cancer between 1999 and 2020 were selected from Web of Science Core Collection on August 23, 2021. Microsoft Excel 2019 and GraphPad Prism 8 were applied to analyze the targeted variables. VOSviewer (version 1.6.16), Citespace (version 5.8.R2), and a widely used online bibliometric platform were used to conduct co-authorship, co-citation, and co-occurrence analysis of countries, institutions, authors, references, and keywords in this field.ResultsA total of 2,749 articles were selected in this study. AI-related research on prostate cancer increased exponentially in recent years, of which the USA was the most productive country with 1,342 publications, and had close cooperation with many countries. The most productive institution and researcher were the Henry Ford Health System and Tewari. However, the cooperation among most institutions or researchers was not close even if the high research outputs. The result of keyword analysis could divide all studies into three clusters: “Diagnosis and Prediction AI-related study”, “Non-surgery AI-related study”, and “Surgery AI-related study”. Meanwhile, the current research hotspots were “deep learning” and “multiparametric MRI”.ConclusionsArtificial intelligence has broad application prospects in prostate cancer, and a growing number of scholars are devoted to AI-related research on prostate cancer. Meanwhile, the cooperation among various countries and institutions needs to be strengthened in the future. It can be projected that noninvasive diagnosis and accurate minimally invasive treatment through deep learning technology will still be the research focus in the next few years.

show abstract

Section: Discussionmentioning

confidence: 99%

The Global Research of Artificial Intelligence on Prostate Cancer: A 22-Year Bibliometric Analysis

Shen

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…New data are then interpreted based on the training data in order to make decisions, such as classifications and predictions. AI models are an evolution of classic nomograms with fewer boundaries and the ability to evolve based on the input data [ 44 , 45 ].…”

Section: Discussionmentioning

confidence: 99%

Role of Perilesional Sampling of Patients Undergoing Fusion Prostate Biopsies

Lombardo

Tema

Nacchia

et al. 2023

Life

View full text Add to dashboard Cite

Recently, researchers have proposed perilesional sampling during prostate biopsies to avoid systematic biopsies of patients at risk of prostate cancer. The aim of our study is to evaluate the role of perilesional sampling to avoid systematic biopsies of patients undergoing fusion biopsies. A prospective cohort of patients undergoing transrectal MRI transrectal fusion biopsies were consecutively enrolled. All the patients underwent systematic biopsies (SB), targeted biopsies (TB) and perilesional biopsies within 10 mm from the lesion (PB). The detection rates of different strategies were determined. A total of 262 patients were enrolled. The median age of those enrolled was 70 years. The mean BMI was 27 kg/m2, and the mean and prostate volume was 52 mL. A PIRADS score ≥ 4 was recorded in 163/262 (40%) patients. Overall, the detection rates of cancer were 43.5% (114/262) and 35% (92/262) for csPCa. The use of the target + peri-target strategy resulted in a detection of 32.8% (86/262) of cancer cases and of 29% (76/262) of csPCa cases (Grade Group > 2). Using the target plus peri-target approach resulted in us missing 18/262 (7%) of the csPCa cases, avoiding the diagnosis of 8/262 (3%) of nsPCa cases. A biopsy strategy including lesional and perilesional sampling could avoid unnecessary prostate biopsies. However, the risk of missing significant cancers is present. Future studies should assess the cost–benefit relationship of different strategies.

show abstract

“…Because characteristics of populations, PCa incidence, and diagnostic approaches frequently change, making accurate real-time predictions adapted to the continuous evolution is challenging [ 39 ]. Continuous updating of risk calculators from the feedback of new cases, integrating the generation of big data, appropriate machine-learning algorithm design [ 40 , 41 ], and federated networks will provide the opportunity to develop future predictive models and risk calculators guaranteeing accurate and enduring overall and specific predictions [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand

Moróte

Borque‐Fernando

Triquell

et al. 2022

Cancers

View full text Add to dashboard Cite

A predictive model including age, PCa family history, biopsy status (initial vs repeat), DRE (normal vs abnormal), serum prostate-specific antigen (PSA), and DRE prostate volume ca-tegory was developed to stratify initial PCa suspicion in 1486 men with PSA > 3 ng/mL and/or abnormal DRE, in whom mpMRI followed; 2- to 4-core TRUS-guided biopsies where Prostate Imaging Report and Data System (PI-RADS) > 3 lesions and/or 12-core TRUS systematic biopsies were performed in one academic institution between 1 January 2016–31 December 2019. The csPCa detection rate, defined as International Society of Uro-Pathology grade group 2 or higher, was 36.9%. An external validation of designed BCN-RC 1 was carried out on 946 men from two other institutions in the same metropolitan area, using the same criteria of PCa suspicion and diagnostic approach, yielded a csPCa detection rate of 40.8%. The areas under the receiver operating characteristic curves of BCN-RC 1 were 0.823 (95% CI: 0.800–0.846) in the development cohort and 0.837 (95% CI: 0.811–0.863) in the validation cohort (p = 0.447). In both cohorts, BCN-RC 1 exhibited net benefit over performing mpMRI in all men from 8 and 12% risk thresholds, respectively. At 0.95 sensitivity of csPCa, the specificities of BCN-RC 1 were 0.24 (95% CI: 0.22–0.26) in the development cohort and 0.34 (95% CI: 0.31–0.37) in the validation cohort (p < 0.001). The percentages of avoided mpMRI scans were 17.2% in the development cohort and 22.3% in the validation cohort, missing between 1.8% and 2% of csPCa among men at risk of PCa. In summary, BCN-RC 1 can stratify initial PCa suspicion, reducing the demand of mpMRI, with an acceptable loss of csPCa.

show abstract

Artificial intelligence for target prostate biopsy outcomes prediction the potential application of fuzzy logic

Cited by 15 publications

References 19 publications

The Global Research of Artificial Intelligence on Prostate Cancer: A 22-Year Bibliometric Analysis

The Global Research of Artificial Intelligence on Prostate Cancer: A 22-Year Bibliometric Analysis

Role of Perilesional Sampling of Patients Undergoing Fusion Prostate Biopsies

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand

Contact Info

Product

Resources

About